Neuroprotection for ischaemic stroke: current status and challenges

Area of Science:

• Neurology
• Translational Medicine

Background:

• Stroke is a leading cause of death and disability globally, with acute ischemic stroke comprising ~80% of cases.
• Current treatments like intravenous thrombolysis have a narrow time window and limited efficacy, treating <10% of patients appropriately.
• Translating promising preclinical neuroprotection studies to clinical success has been challenging.

Purpose of the Study:

• To analyze reasons for the failure of neuroprotective agents in clinical stroke trials.
• To explore novel strategies for acute ischemic stroke treatment, including neuroprotection and neurorepair.
• To discuss future therapeutic approaches combining thrombolysis, neuroprotection, and neurorepair.

Main Methods:

• Review of preclinical and clinical studies on neuroprotection in acute ischemic stroke.
• Analysis of challenges in translating animal model successes to human trials.
• Examination of neurorepair strategies, including cell-based therapies and ischemic conditioning.

Main Results:

• Numerous neuroprotective agents showed promise in animal models but failed in clinical trials.
• Reasons for clinical failure include differences between animal models and human stroke, and the complexity of the ischemic cascade.
• Combination therapies and neurorepair strategies show potential for improved outcomes.

Conclusions:

• Future acute ischemic stroke therapy likely requires a multimodal approach.
• Combining thrombolysis with neuroprotection (to stabilize the penumbra) and neurorepair (cell therapy, rehabilitation) is a promising direction.
• Addressing secondary prevention with antithrombotics is crucial for long-term patient management.